The gain came after the biotech announced that it had completed the submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for aducanumab as a treatment for Alzheimer's disease.However, hopes were dashed last year after Biogen halted two late-stage studies of aducanumab after an independent data-monitoring committee determined that the experimental drug was unlikely to be effective.